Binding of inhibitory fatty acids is responsible for the enhancement of UDP-glucuronosyltransferase 2B7 activity by albumin: Implications for in vitro-in vivo extrapolation

Journal of Pharmacology and Experimental Therapeutics

Volumn 321, Issue 1, 2007, Pages 137-147

  Rowland, Andrew ^a   Gaganis, Paraskevi ^a   Elliot, David J ^a   Mackenzie, Peter I ^a   Knights, Kathleen M ^a   Miners, John O ^a,b  

^a FLINDERS UNIVERSITY   (Australia)

^b FLINDERS MEDICAL CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ARACHIDONIC ACID; BOVINE SERUM ALBUMIN; GLUCURONOSYLTRANSFERASE 2B7; HYMECROMONE; LINOLEIC ACID; OLEIC ACID; RECOMBINANT ENZYME; UNSATURATED FATTY ACID; ZIDOVUDINE;

ARTICLE; CONTROLLED STUDY; DRUG BINDING; DRUG GLUCURONIDATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ALBUMINS; ANIMALS; ANTI-HIV AGENTS; BLOTTING, WESTERN; CATTLE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DATA INTERPRETATION, STATISTICAL; FATTY ACIDS; GLUCURONIDES; GLUCURONOSYLTRANSFERASE; HUMANS; HYMECROMONE; KINETICS; MICROSOMES; PROTEIN BINDING; RECOMBINANT PROTEINS; SERUM ALBUMIN; SERUM ALBUMIN, BOVINE; ZIDOVUDINE;

EID: 33947398317     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.106.118216     Document Type: Article

References (41)

1. Boase S and Miners JO (2002) In vitro - in vivo correlations for drugs eliminated by glucuronidation: investigation with the model substrate zidovudine. Br J Clin Pharmacol 54:493-503.
2. Bowalgaha K, Elliot DJ, Mackenzie PI, Knights KM, Swedmark S, and Miners JO (2005) Naproxen and desmethylnaproxen glucuronidation by human liver microsomes and recombinant human UDP-glucuronosyltransferases (UGT): role of UGT2B7 in the elimination of naproxen. Br J Clin Pharmacol 60:423-433.
3. Carlile DJ, Hakooz N, Bayliss MK, and Houston JB (1999) Microsomal prediction of in vivo clearance of CYP2C9 substrates in humans. Br J Clin Pharmacol 47:625-635.
4. Court MH, Krishnaswamy S, Hoa Q, Duan SX, Patten CJ, von Moltke LL, and Greenblatt DJ (2003) Evaluation of 3′-azido-3′-deoxymethymidine, morphine, and codeine as probe substrates for UDP-glucuronosyltransferase 2B7 (UGT2B7) in human liver microsomes: specificity and influence of the UGT2B7*2 polymorphism. Drug Metab Dispos 31:1125-1133.
5. Engtrakul JJ, Foti RS, Strelevitz TJ, and Fisher MB (2005) Altered AZT (3′-azido-3′-deoxythymidine) glucuronidation kinetics in liver microsomes as an explanation for underprediction of in vivo clearance: comparison to hepatocytes and effect of incubation environment. Drug Metab Dispos 33:1621-1627.
6. Folch J, Lees M, and Stanley GHS (1956) A simple method for the isolation and purification of total lipids from animal tissue. J Biol Chem 226:497-509.
7. Griffin SJ and Houston JB (2004) Prediction of in vitro intrinsic clearance from hepatocytes: comparison of suspensions and monolayer cultures. Drug Metab Dispos 33:115-120.
8. Hamilton JA (2002) How fatty acids bind to proteins: the inside story from protein structures. Prostaglandins Leukot Essent Fatty Acids 67:65-72.
9. Houston JB (1994) Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem Pharmacol 47:1469-1479.
10. Houston JB and Kenworthy KE (2000) In vitro - in vivo scaling of CYP kinetic data not consistent with the classical Michaelis Menten model. Drug Metab Dispos 28:246-254.
11. Ito K, Iwatsubo T, Kanamitsu S, Nakajima, and Sugiyama Y (1998) Quantitative prediction of in vivo drug clearance from in vitro data on metabolism, together with binding and transport. Annu Rev Pharmacol Toxicol 38:461-499.
12. Ito K and Houston JB (2004) Comparison of the use of liver models for predicting drug clearance using in vitro kinetic data from hepatic microsomes and isolated hepatocytes. Pharm Res (NY) 21:785-792.
13. Ito K and Houston JB (2005) Prediction of human drug clearance from in vitro and preclinical data using physiologically based and empirical approaches. Pharm Res (NY) 22:103-112.
14. Iwatsubo T, Hirota N, Ooie T, Suzuki H, Shimada N, Chiba K, Ishizaki T, Green CE, Tyson CA, and Sugiyama Y (1997) Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data. Pharmacol Ther 73:147-171.
15. Jude AR, Little JM, Czernik PJ, Tephly TR, Grant DF, and Radominska-Pandya (2001) Glucuronidation of linoleic acid diols by human microsomal and recombinant UDP-glucuronosyltransferases: identification of UGT2B7 as the major isoforms involved. Arch Biochem Biophys 389:176-186.
16. Kapitulnik J, Weil E, Rabinowitz R, and Krausz (1987) Fetal and adult human liver differ markedly in the fluidity and lipid composition of their microsomal membranes. Hepatology 7:55-60.
17. Little JM, Kurkela M, Sonka J, Jantti S, Ketola R, Bratton S, Finel M, and Radominska-Pandya A (2004) Glucuronidation of oxidized fatty acids and prostaglandins B1 and E2 by human hepatic and recombinant UDP- glucuronosyltransferases. J Lipid Res 45:1694-1703.
18. Ludden LK, Ludden TM, Collins JM, Pentikis HS, and Strong JM (1997) Effect of albumin on estimations, in vitro, of phenytoin Vmax and Km values; implications for clinical correlation. J Pharmacol Exp Ther 282:391-396.
19. McGinnity DF, Soars MG, Urbanowicz RA, and Riley RJ (2005) Evaluation of fresh and cryopreserved hepatocytes as in vitro drug metabolism tools for the prediction of metabolic clearance. Drug Metab Dispos 32:1247-1253.
20. McLure JA, Miners JO, and Birkett DJ (2000) Non-specific binding of drugs to human liver microsomes. Br J Clin Pharmacol 49:453-461.
21. Miners JO, Knights KM, Houston JB, and Mackenzie PI (2006) In vitro-in vivo correlation for drugs and other compounds eliminated by glucuronidation in humans: pitfalls and promises. Biochem Pharmacol 71:1531-1539.
22. Miners JO, Smith PA, Sorich MJ, McKinnon RA, and Mackenzie PI (2004) Predicting human drug glucuronidation parameters: application of in vitro and in silico modeling approaches. Annu Rev Pharmacol Toxicol 44:1-25.
23. Mistry M and Houston JB (1987) Glucuronidation in vitro and in vivo. Comparison of intestinal and hepatic conjugation of morphine, naloxone, and buprenorphine. Drug Metab Dispos 15:710-717.
24. Naritomi Y, Terashita S, Kagayama A, and Sugiyama Y (2003) Utility of hepatocytes in predicting drug metabolism: comparison of hepatic intrinsic clearance in rats and humans in vivo and in vitro. Drug Metab Dispos 31:580-588.
25. Proctor NJ, Tucker GT, and Rostami-Hodjegan A (2004) Predicting drug clearance from recombinantly expressed CYPs: intersystem extrapolation factors. Xenobiotica 34:151-178.
26. Riley RJ, McGinnity DF, and Austin RP (2005) A unified model for predicting human hepatic, metabolic clearance from in vitro intrinsic clearance data in hepatocytes and microsomes. Drug Metab Dispos 33:1304-1311.
27. Rowland A, Elliot DJ, Williams JA, Mackenzie PI, Dickinson RG, and Miners JO (2006) In vitro characterization of lamotrigine N2-glucuronidation and the lamotrigine-valproic acid interaction. Drug Metab Dispos 34:1055-1062.
28. Soars MG, Burchell B, and Riley RJ (2002) In vitro analysis of human drug glucuronidation and prediction of in vivo metabolic clearance. J Pharmacol Exp Ther 301:382-390.
29. Stone AN, Mackenzie PI, Galetin A, Houston JB, and Miners JO (2003) Isoform selectivity and kinetics of morphine 3- and 6-glucuronidation by human UDP-glucuronosyltransferases: evidence for atypical glucuronidation kinetics by UGT2B7. Drug Metab Dispos 31:1086-1089.
30. Tang C, Lin Y, Rodrigues AD, and Lin JH (2002) Effect of albumin on phenytoin and tolbutamide metabolism in human liver microsomes: an impact more than protein binding. Drug Metab Dispos 30:648-654.
31. Tsoutsikos P, Miners JO, Stapleton A, Thomas A, Sallustio BC, and Knights KM (2004) Evidence that unsaturated fatty acids are potent inhibitors of renal UDP-glucuronosyltransferases (UGT): kinetic studies using human kidney cortical microsomes and recombinant UGT1A9 and UGT2B7. Biochem Pharmacol 67:191-199.
32. Turgeon D, Chouinard S, Belanger P, Picard S, Labbe JF, Borgeat P, and Belanger A (2003) Glucuronidation of arachidonic and linoleic acid metabolites by human UDP-glucuronosyltransferases. J Lipid Res 44:1182-1190.
33. Uchaipichat V, Mackenzie PI, Guo XH, Gardner-Stephen D, Galetin A, Houston JB, and Miners JO (2004) Human UDP-glucuronosyltransferases: isoform selectivity and kinetics of 4-methylumbelliferone and 1-napthol glucuronidation, effects of organic solvents, and inhibition by diclofenac and probenecid. Drug Metab Dispos 32:413-423.
34. Uchaipichat V, Winner LK, Mackenzie PI, Elliot DJ, Williams JA, and Miners JO (2006) Quantitative prediction of in vivo inhibitory drug interactions involving glucuronidated drugs from in vitro data: the effect of fluconazole on zidovudine glucuronidation. Br J Clin Pharmacol 61:427-439.
35. von Moltke LL, Greenblatt DJ, Schmider J, Wright CE, Harmatz JS, and Shader RI (1998) In vitro approaches for predicting drug interactions in vivo. Biochem Pharmacol 55:113-122.
36. Wang JS, Wen X, Backman JT, and Neuvonen PJ (2002) Effect of albumin and cytosol on enzyme kinetics of tolbutamide hydroxylation and on inhibition of CYP2C9 by gemfibrozil in human liver microsomes. J Pharmacol Exp Ther 302:43-49.
37. Ward KW (2005) Recent advances in pharmacokinetic extrapolation from preclinical data to humans. Expert Opin Drug Metab Toxicol 1:583-594.
38. Waskell L, Koblin D, and Canova-Davis E (1982) The lipid composition of human liver microsomes. Lipids 17:317-320.
39. Wienkers LC and Heath TG (2005) Predicting in vivo drug interactions from in vitro drug discovery data. Nat Rev Drug Discov 4:825-833.
40. Williams JA, Hyland R, Jones BC, Smith DA, Hurst S, Goosen TC, Peterkin V, Koup JR, and Ball SE (2004) Drug-drug interactions for UDP- glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos 32:1201-1208.
41. Zhou Q, Matsumoto S, Ding LR, Fischer NE, and Inaba T (2004) The comparative interaction of human and bovine serum albumins with CYP2C9 in human liver microsomes. Life Sci 75:2145-2155.